Related Experiment Video

Updated: Jan 22, 2026

In Silico Clinical Trials for Cardiovascular Disease
09:09

In Silico Clinical Trials for Cardiovascular Disease

Published on: May 27, 2022

2.2K

Hispanic representation in diabetes cardiovascular outcomes trials

A Taylor Kelley1,2,3,4, Kara Mizokami-Stout1,2,3,4,5, Matthew J O'Brien6

  • 1Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA.

BMJ Open Diabetes Research & Care
|June 28, 2019
PubMed

Insights

Representation of Hispanic/Latino adults in diabetes trials is similar to the US population. However, trial participants differ in age, sex, and obesity, potentially limiting generalizability of findings for novel antidiabetic drugs.

Area of Science:

  • Clinical research
  • Cardiovascular outcomes
  • Diabetes mellitus

Background:

  • Diabetes cardiovascular outcomes trials (CVOTs) are crucial for evaluating novel antidiabetic drugs.
  • Ensuring diverse representation in clinical trials is essential for generalizable results.

Purpose of the Study:

  • To examine Hispanic/Latino representation in diabetes CVOTs for novel antidiabetic drugs.
  • To compare demographic and anthropometric characteristics of Hispanic/Latino participants in CVOTs with the general US Hispanic/Latino population with diabetes.

Main Methods:

  • A systematic review of diabetes CVOTs published from January 2008 to October 2018 was conducted.
  • Hispanic/Latino representation, age, gender, and body mass index (BMI) in trials were compared to data from the National Health Examination and Nutrition Survey (NHANES) for US adults with diabetes.

Main Results:

  • Hispanic/Latino individuals constituted 18.5% of trial subjects, mirroring their proportion in the US adult diabetic population.
  • Trial participants were significantly younger, more frequently female, and had higher BMI compared to US Hispanics/Latinos with diabetes.
  • Participants from at least 10 Latin American countries were included across the 10 analyzed trials.

Conclusions:

  • While Hispanic/Latino representation in diabetes CVOTs is comparable to the US population, significant demographic and anthropometric differences exist between trial subjects and the broader US Hispanic/Latino population with diabetes.
  • These disparities may impact the generalizability and applicability of findings from novel antidiabetic drug trials to diverse Hispanic/Latino communities.
Abstract

Keywords:
disparitieshispanictype 2 diabetes

More Related Videos

Hydra, a Computer-Based Platform for Aiding Clinicians in Cardiovascular Analysis and Diagnosis07:51

Hydra, a Computer-Based Platform for Aiding Clinicians in Cardiovascular Analysis and Diagnosis

Published on: September 26, 2018

8.0K
Regulatory T cells: Therapeutic Potential for Treating Transplant Rejection and Type I Diabetes16:26

Regulatory T cells: Therapeutic Potential for Treating Transplant Rejection and Type I Diabetes

Published on: August 20, 2007

6.2K

Related Concept Videos

Control Volume and System Representations01:16

Control Volume and System Representations

Two key frameworks are employed to analyze mass, energy, and momentum transfer: the control volume approach and the system approach. These frameworks offer different perspectives, depending on whether the focus is on a specific region in space (control volume approach) or a defined mass of fluid (system approach).
The control volume approach considers a stationary region in space through which fluid flows. This region is bounded by a control surface.  For instance, in the case of water...
1.5K
State Space Representation01:27

State Space Representation

The frequency-domain technique, commonly used in analyzing and designing feedback control systems, is effective for linear, time-invariant systems. However, it falls short when dealing with nonlinear, time-varying, and multiple-input multiple-output systems. The time-domain or state-space approach addresses these limitations by utilizing state variables to construct simultaneous, first-order differential equations, known as state equations, for an nth-order system.
Consider an RLC circuit, a...
540
Graphical and Analytic Representation of Sinusoids01:20

Graphical and Analytic Representation of Sinusoids

Analyzing two sinusoidal voltages with equal amplitude and period but different phases on an oscilloscope, an instrument used to display and analyze waveforms, involves a three-step process.
The first step is measuring the peak-to-peak value, which is twice the amplitude of the sinusoid. This provides information about the maximum voltage swing of the waveform.
Secondly, the period and angular frequency are determined. The period is the time taken for one complete cycle of the waveform, while...
921
Vector Representation of Complex Numbers01:16

Vector Representation of Complex Numbers

Complex numbers, represented in Cartesian coordinates, can also be visualized as vectors. These vectors can be expressed in polar form, emphasizing their magnitude and angle. When a complex number is input into a function, the output is another complex number, highlighting the function's zero point from which the vector representation can originate.
Consider a function defined as the product of the complex factors in the numerator divided by the product of the complex factors in the...
498
Clinical Trials01:16

Clinical Trials

Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
10.2K
Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
4.6K